DD, appreciate the share count part especially. However, you need to include the cash that will come from stock options and warrants to the net debt calc. More importantly, what's the denominator? What does this imply on an EV/EBITDA basis? None of these are answered at this point as we don't know what this company will be able to make. Let's see the sales potential a bit being realised and then things will be clearer in my view. Also, from a buyer's perspective, adding implant to their portfolio and being able to offer full service (for EDS manufacturers) could mean a lot and multiples can go off the roof given the growth profile and lower implied multiples. Too early to talk about these...
News 
Market Data 
Discover 
AI
